J&J Stock Hits New High Amid Analyst Optimism

Johnson & Johnson's stock price has hit an all-time high of $276.50, marking a significant upward trend for the company. This milestone reflects investor confidence in Johnson & Johnson's market strategies and potential for continued growth.

The healthcare giant has delivered a total return of 55.73% over the past year, with its market capitalization standing at $660 billion and a P/E ratio of 31.38. The company has also maintained its dividend for 56 consecutive years, a testament to its stability and reliability.

Analyst firms have been upbeat about Johnson & Johnson's prospects, with UBS raising its price target to $320 from $280, and Guggenheim increasing its target to $287 from $270. Raymond James also raised its target to $280 from $265, citing the recent FDA approval of Johnson & Johnson's Ottava robotic surgery platform.